Home Cart Sign in  
Chemical Structure| 432001-69-9 Chemical Structure| 432001-69-9

Structure of Skp2 Inhibitor C1
CAS No.: 432001-69-9

Chemical Structure| 432001-69-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Skp2 inhibitor C1 is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.

Synonyms: SKPin C1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Skp2 Inhibitor C1

CAS No. :432001-69-9
Formula : C18H13BrN2O4S2
M.W : 465.34
SMILES Code : O=C(O)COC1=CC=C(Br)C=C1/C=C(SC(N2CC3=CC=CN=C3)=S)/C2=O
Synonyms :
SKPin C1
MDL No. :MFCD03705291
InChI Key :IYCJJVVXEHZJHE-CHHVJCJISA-N
Pubchem ID :5733396

Safety of Skp2 Inhibitor C1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PIG1 cells 16.71 μM (IC50) 4 days Evaluate the inhibitory effect of SKPin C1 on normal melanocyte PIG1 cells, results showed IC50 of 16.71 μM, with weaker inhibition PMC6549483
OM431 cells 1.83 μM (IC50) 4 days Evaluate the inhibitory effect of SKPin C1 on OM431 cells, results showed IC50 of 1.83 μM, significantly inhibiting cell growth PMC6549483
MUM2B cells 0.86 μM (IC50) 4 days Evaluate the inhibitory effect of SKPin C1 on MUM2B cells, results showed IC50 of 0.86 μM, significantly inhibiting cell growth PMC6549483

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice MUM2B xenograft model Intraperitoneal injection 20 mg/kg Once a week for 4 weeks Evaluate the anti-tumor effect of SKPin C1 in vivo, results showed significant reduction in tumor size and weight PMC6549483
C57BL/6J mice High-fat diet-induced non-alcoholic fatty liver disease model Oral 5 mg/kg/day Once daily for four weeks To investigate the effects of ezetimibe on high-fat diet-induced non-alcoholic fatty liver disease. Results showed that ezetimibe significantly reduced liver steatosis and fibrosis, improved insulin resistance, and decreased SKP2 protein expression. PMC4227427

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.21mL

10.74mL

2.15mL

1.07mL

21.49mL

4.30mL

2.15mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories